Core Viewpoint - Elevation Oncology has decided to discontinue the development of EO-3021, an antibody-drug conjugate for treating advanced gastric and gastroesophageal junction cancers, due to disappointing trial data [1][3]. Group 1: Clinical Trial Results - EO-3021 as a monotherapy showed an objective response rate of 22.2%, with 1 confirmed complete response and 7 confirmed partial responses among 36 evaluable patients [2]. - The disease control rate for EO-3021 was reported at 72.2% for patients with Claudin 18.2 expression in ≥20% of tumor cells [2]. - Despite being generally well-tolerated in a safety analysis of 85 enrolled patients, EO-3021 did not meet the company's success criteria [3]. Group 2: Strategic Decisions - The company will continue to develop EO-1022, a HER3 ADC for patients with HER3-expressing solid tumors, with plans to file an Investigational New Drug (IND) application in 2026 [3]. - Elevation Oncology is evaluating strategic options to maximize shareholder value and is implementing a workforce reduction of approximately 70%, resulting in costs of about $3 million [4]. Group 3: Financial Position - As of December 31, Elevation Oncology reported cash, cash equivalents, and marketable securities totaling $93.2 million, which is expected to fund operations into the second half of 2026 [5]. - Following the announcement, ELEV stock experienced a decline of 47.1%, trading at 25 cents [5].

Core Insights - Elevation Oncology has decided to discontinue the development of EO-3021, a Claudin 18.2 ADC, due to insufficient efficacy data despite a reasonable safety profile [1][3] - The company will continue to advance EO-1022, a HER3 ADC, with plans to present preclinical data at the AACR Annual Meeting in 2025 and file an IND application in 2026 [1][7] - A workforce reduction of approximately 70% is being implemented, with estimated costs of around $3 million associated with this restructuring [4][6] Development Updates - EO-3021 demonstrated an objective response rate (ORR) of 22.2% and a disease control rate (DCR) of 72.2% in a Phase 1 trial involving 36 evaluable patients [2] - The safety profile of EO-3021 was generally well-tolerated, with minimal hematological toxicity and no peripheral neuropathy observed [2] Financial Position - As of December 31, 2024, Elevation Oncology reported cash, cash equivalents, and marketable securities totaling $93.2 million, which is expected to fund operations into the second half of 2026 [6]

Core Insights - Elevation Oncology is advancing its Claudin 18.2 ADC program, EO-3021, for advanced gastric/gastroesophageal junction cancer, with initial data from combination cohorts expected in Q4 2025 or Q1 2026 [1][2] - The company has implemented prospective Claudin 18.2 testing in its ongoing Phase 1 trial to better identify patients likely to benefit from EO-3021 [2][3] - Financial results for the year ended December 31, 2024, show an increase in cash reserves and R&D expenses, reflecting ongoing investment in clinical trials [5][6][14] Clinical Development - EO-3021 is currently being evaluated in combination with dostarlimab and ramucirumab in Phase 1 clinical trials [1][3] - Preclinical data presented at ESMO-IO 2024 demonstrated superior tumor growth inhibition when EO-3021 was combined with either a PD-1 inhibitor or a VEGFR2 inhibitor [3] - The company plans to file an Investigational New Drug (IND) application for its HER3 ADC, EO-1022, in 2026 [1][4][11] Financial Performance - As of December 31, 2024, Elevation Oncology reported cash, cash equivalents, and marketable securities totaling $93.2 million, up from $83.1 million in 2023 [5][14] - R&D expenses for Q4 2024 were $6.6 million, an increase from $4.7 million in Q4 2023, driven by clinical trial costs [6][13] - The net loss for Q4 2024 was $10.4 million, compared to $7.9 million in Q4 2023 [8][13] Upcoming Milestones - The company expects to report additional safety and efficacy data from the EO-3021 monotherapy trial in Q2 2025 [11] - Initial data from the combination cohorts of the EO-3021 trial is anticipated in Q4 2025 or Q1 2026 [1][11] - Preclinical data for EO-1022 will be presented at the AACR Annual Meeting in 2025 [1][11]